Premium
Triple negative phenotype and N‐ratio are important for prognosis in patients with stage IIIB non‐inflammatory breast carcinoma
Author(s) -
Mersin Hakan,
Yildirim Emin,
Berberoglu Ugur,
Gulben Kaptan
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21411
Subject(s) - medicine , hazard ratio , confidence interval , proportional hazards model , stage (stratigraphy) , univariate analysis , gastroenterology , pathological , triple negative breast cancer , breast carcinoma , oncology , carcinoma , multivariate analysis , breast cancer , cancer , paleontology , biology
Background and Objectives The aim is to evaluate novel prognostic factors such as triple negative (TN) phenotype and ratio between positive nodes and total dissected lymph nodes (N‐ratio) in stage IIIB breast carcinoma patients. Methods In this retrospective study, primary endpoints were local recurrence (LR), distant recurrence (DR), and overall survival (OS). Univariate and multivariate prognostic factor analyses were carried out using Cox and Kaplan–Meier methods in the data of 185 patients. Results The median observation time was 36 (range 16–86) months. Pathological tumor size (continuous [cont.], P = 0.002; Hazard ratio [HR], 1.2; 95% confidence interval [CI], 1.1–1.3) and N‐ratio (cont., P < 0.0001; HR, 1.02; CI, 1.01–1.03) were strongly associated with LR. Tumor phenotype (triple vs. non‐triple, P = 0.002; HR, 2.6; CI, 1.4–4.7), N‐ratio (cont., P = 0.01; HR, 1.02; CI, 1.01–1.03) and pathological tumor size (cont., P = 0.003; HR, 1.2; CI, 1.1–1.3) for DR, and also tumor phenotype (triple vs. non‐triple, P < 0.0001; HR, 3.7; CI, 1.8–7.5), N‐ratio (cont., P = 0.03; HR, 1.02; CI, 1.01–1.03) and pathological tumor size (cont., P = 0.006; HR, 1.3; CI, 1.2–1.4) for OS were the most important prognostic factors. Conclusions N‐Ratio and TN phenotype were the most important prognostic factors for stage IIIB breast carcinoma patients. J. Surg. Oncol. 2009;100:681–687. © 2009 Wiley‐Liss, Inc.